Bitopertin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bitopertin
DrugBank Accession Number
DB12426
Background

Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 543.46
Monoisotopic: 543.106274451
Chemical Formula
C21H20F7N3O4S
Synonyms
  • Bitopertin
External IDs
  • R-1678
  • RG-1678
  • RO-4917838
  • RO-4917939

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Pyridinylpiperazines
Alternative Parents
N-arylpiperazines / Benzenesulfonyl compounds / Benzamides / Phenoxy compounds / Phenol ethers / Dialkylarylamines / Benzoyl derivatives / Alkyl aryl ethers / Aminopyridines and derivatives / Imidolactams
show 9 more
Substituents
Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Amine / Aminopyridine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzamide
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Q8L6AN59YY
CAS number
845614-11-1
InChI Key
YUUGYIUSCYNSQR-LBPRGKRZSA-N
InChI
InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3/t12-/m0/s1
IUPAC Name
1-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-4-(5-methanesulfonyl-2-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzoyl)piperazine
SMILES
C[C@H](OC1=CC=C(C=C1C(=O)N1CCN(CC1)C1=C(F)C=C(C=N1)C(F)(F)F)S(C)(=O)=O)C(F)(F)F

References

General References
Not Available
PubChem Compound
24946690
PubChem Substance
347828669
ChemSpider
25034798
BindingDB
50322423
ChEMBL
CHEMBL1171829
ZINC
ZINC000053294258
Wikipedia
Bitopertin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentSchizophrenia6
2Active Not RecruitingTreatmentErythropoietic Protoporphyria (EPP)1
2CompletedTreatmentBeta-Thalassemia1
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2CompletedTreatmentSchizophrenia2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0508 mg/mLALOGPS
logP4.09ALOGPS
logP3.46Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)19.71Chemaxon
pKa (Strongest Basic)2.88Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area79.81 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity116.16 m3·mol-1Chemaxon
Polarizability45.8 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0000090000-54686dc76c8943649092
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-0000090000-35c0fc94cd7be6e1df10
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-1000490000-7db098d66083310ac3aa
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-0000090000-1d246da731d87bd2a62f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4j-0092310000-74fc07d302ee2eace308
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004s-2294630000-5f9b1c18043c603c255e
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-209.97888
predicted
DeepCCS 1.0 (2019)
[M+H]+212.37444
predicted
DeepCCS 1.0 (2019)
[M+Na]+218.64514
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:21 / Updated at February 21, 2021 18:53